Who Should-and Can-Get Lecanemab, the New Alzheimer Disease Drug?

JAMA. 2023 Oct 17;330(15):1411-1415. doi: 10.1001/jama.2023.14443.
No abstract available

Plain language summary

This Medical News story examines the complexity of determining who to treat with lecanemab, the new Alzheimer disease drug.

MeSH terms

  • Alzheimer Disease* / drug therapy
  • Amyloid beta-Peptides
  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Humans

Substances

  • Amyloid beta-Peptides
  • lecanemab
  • Antibodies, Monoclonal, Humanized